Drug Profile
Reteplase biosimilar - Nanogen Biopharmaceutical
Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Myocardial-infarction in Vietnam (IV, Injection)
- 18 Mar 2014 Early research in Myocardial infarction in Vietnam (IV)